The US Food and Drug Administration has approved Roche’s Wilserdly (giredestrant) as a new once-daily oral treatment for advanced breast cancer that has stopped responding to hormone therapy, offering patients an alternative to injections and infusions.
Wilserdly is to be taken with everolimus for adults with oestrogen receptor (ER)-positive, HER2-negative breast cancer that carries an ESR1 mutation and has recurred during or after endocrine therapy, or has progressed after at least one endocrine-based regimen for metastatic disease. The mutation, which can develop as tumours adapt to hormone-blocking drugs, is found in a substantial share of patients whose cancer returns after endocrine treatment.
Approval rests on the phase 3 evERA trial of 373 patients. Among the 207 whose tumours carried an ESR1 mutation, those given Wilserdly plus everolimus went a median of 10 months before their disease worsened, compared with 5.5 months for patients on standard endocrine therapy plus everolimus, a 62 per cent reduction in the risk of progression or death. Confirmed tumour responses were seen in 27 per cent of patients on the new combination, against 14 per cent in the control group.
The FDA acted four weeks ahead of its 18 December goal date, reviewing the application jointly with Health Canada and Israel’s Ministry of Health under its Project Orbis programme. It also authorised Foundation Medicine’s FoundationOne Liquid CDx blood test to identify the ESR1 mutations that qualify patients for the drug.
It is not yet known whether the combination helps patients live longer: overall survival data were immature at the time of approval, so the evidence so far rests on delaying progression rather than extending life.
Roche told the news service STAT that the list price would be about $270,000 a year. A further decision is due by 30 November, when the FDA is expected to rule on using Wilserdly after surgery in earlier-stage breast cancer, based on the lidERA trial; Roche has said that, if approved, it would be the first new adjuvant endocrine therapy in more than 20 years.
Sources: US Food and Drug Administration, “FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer”, 16 November 2026, https://www.fda.gov/drugs/cancer-approvals/oncology-cancerhematologic-malignancies-approval-notifications?param=799b05dc ; Roche, “FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer”, 15 November 2026, https://www.roche.com/media/releases/med-cor-2026-11-16b
